Qube Research & Technologies LTD Allakos Inc. Transaction History

Qube Research & Technologies LTD

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$1.72 - $3.18 $221,974 - $410,394	-129,055 Reduced 91.16%	12,514 $34,000
Q3 2023 Nov 13, 2023	SELL	$2.13 - $5.55 $298,291 - $777,238	-140,043 Reduced 49.73%	141,569 $321,000
Q2 2023 Aug 14, 2023	SELL	$3.6 - $5.25 $898,527 - $1.31 Million	-249,591 Reduced 46.99%	281,612 $1.23 Million
Q1 2023 May 15, 2023	BUY	$4.3 - $8.27 $2.04 Million - $3.93 Million	474,711 Added 840.32%	531,203 $2.36 Million
Q4 2022 Feb 14, 2023	BUY	$5.66 - $8.42 $56,396 - $83,896	9,964 Added 21.42%	56,492 $475,000
Q3 2022 Nov 14, 2022	BUY	$3.02 - $6.12 $140,514 - $284,751	46,528 New	46,528 $285,000
Q2 2022 Aug 15, 2022	SELL	$2.6 - $6.14 $168,493 - $397,902	-64,805 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$5.08 - $9.81 $329,209 - $635,737	64,805 New	64,805 $369,000
Q3 2021 Nov 12, 2021	SELL	$76.53 - $110.43 $622,341 - $898,016	-8,132 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$85.37 - $114.1 $694,228 - $927,861	8,132 New	8,132 $694,000
Q1 2020 May 15, 2020	SELL	$44.49 - $93.39 $535,081 - $1.12 Million	-12,027 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$66.49 - $137.73 $799,675 - $1.66 Million	12,027 New	12,027 $1.15 Million

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $89.8M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.